Today's gain appears to be a partial recovery from yesterday's nearly 4% drop, which was driven by the FDA delay and lawsuit news. The Nvidia partnership and Ventyx acquisition provide offsetting positive narratives, with Jefferies maintaining a Buy rating and $1,300 price target. This follows a pattern seen earlier this week where the Nvidia announcement drove gains on Jan 12-13 before the negative news hit.
This is a permanent link to this specific analysis (ID: 2358)
Back to Dashboard